Disseminated histoplasmosis and aids: Relapse and late mortality in endemic area in North-Eastern Brazil

Mycoses

Volumn 56, Issue 5, 2013, Pages 520-526

  Dasmasceno, Lisandra Serra ^a,b   Novaes Jr, Alberto Ramos ^a   Alencar, Carlos Henrique Morais ^a,c   Lima, Daniel Teixeira ^a   Sidrim, José Júlio Costa ^a   Gonçalves, Maria Vânia Freitas ^b   de Mesquita, Jacó Ricarte Lima ^b   Leitão, Terezinha do Menino Jesus Silva ^a,b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Sao Jose Infectious Diseases Hospital   (Brazil)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

AIDS; Disseminated histoplasmosis; Mortality; Mycoses

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; ITRACONAZOLE; LOPINAVIR PLUS RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISSEMINATED HISTOPLASMOSIS; ENDEMIC DISEASE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT INFECTION; RELAPSE; RETROSPECTIVE STUDY; SYMPTOM; VIRUS LOAD;

AIDS; DISSEMINATED HISTOPLASMOSIS; MORTALITY; MYCOSES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; BRAZIL; FEMALE; FOLLOW-UP STUDIES; HISTOPLASMOSIS; HUMANS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84881026337     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12067     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention. 1987 revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep, 1987; 36 (Suppl. 1): 1-15.
2. Ferreira MS, Borges AS. Histoplasmose. Rev Soc Bras Med Trop 2009; 42: 192-8.
3. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007; 20: 115-32.
4. Zerbe CS, Holland SM. Disseminated histoplasmosis in persons with interferon-receptor 1 deficiency. Clin Infect Dis 2005; 41: 38-41.
5. Severo LC, Oliveira FM, Irion K, Porto NS, Londero AT. Histoplasmosis in Rio Grande do Sul, Brazil: a 21 year experience. Rev Inst Med Trop Sao Paulo 2001; 43: 183-7.
6. Tobon AM, Agudelo CA, Rosero DS et al. Disseminated histoplasmosis: a comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals. Am J Trop Med Hyg 2005; 73: 576-82.
7. Pietrobon D, Negro-Marquinez L, Kilstein J, Galíndez J, Greca A, Battagliotti C. Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment. Enferm Infecc Microbiol Clin 2004; 22: 156-9.
8. Casotti JA, Motta TQR, Ferreira Júnior CUG, Cerutti Junior C. Disseminated histoplasmosis in HIV positive patients in Espirito Santo state, Brazil: a clinical-laboratory study of 12 cases (1999-2001). Braz J Infect Dis 2006; 10: 327-30.
9. Unis G, Oliveira FM, Severo LC. Histoplasmose disseminada no Rio Grande do Sul. Rev Soc Bras Med Trop 2004; 37: 463-8.
10. Mora DJ, dos Santos CT, Silva-Vergara ML. Disseminated histoplasmosis in acquired immunodeficiency syndrome patients in Uberaba, MG, Brazil. Mycoses 2007; 51: 136-40.
11. Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2009; 58: 1-216.
12. Wheat LJ, Kauffman CA. Histoplasmosis. Infect Dis Clin North Am 2003; 17: 1-19.
13. Couppie P, Aznar C, Carme B, Nacher M. American histoplasmosis in developing countries with a special focus on patients with HIV: diagnosis, treatment, and prognosis. Curr Opin Infect Dis 2006; 19: 443-9.
14. Gutierrez ME, Canton A, Sosa N, Puga E, Talavera L. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. Clin Infect Dis 2005; 40: 1199-202.
15. Goldman M, Zackin R, Fichtenbaum CJ et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004; 38: 1485-9.
16. Pontes LB, Leitão TMJS, Lima GG, Gerhard ES, Fernandes TA. Características clínico-evolutivas de 134 pacientes com histoplasmose disseminada associada a SIDA no Estado do Ceará. Rev Soc Bras Med Trop 2010; 43: 27-31.
17. Karimi K, Wheat LJ, Connoly P et al. Differences in histoplasmosis in patients with acquired immunodeficiency in the United States and Brazil. J Infect Dis 2002; 186: 1655-61.
18. Negroni R, Helou SH, Lopez-Daneri GRobles AM, Arechavala AI, Bianchi MH. Interrupición de la prophilaxis secundaria antifungica em la histoplasmosis asociada al sida. Rev Iberoam Micol 2004; 21: 75-8.
19. Sun HY, Chen MY, Hsieh SM, Hung CC, Chang SC. Successful discontinuation of secondary prophylaxis for histoplasmosis after higly active antiretroviral therapy. J Formos Med Assoc 2004; 103: 546-8.
20. Wheat J, Sarosi G, McKinsey D et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000; 30: 688-95.
21. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 807-25.
22. BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Critérios de definição de casos de AIDS em adultos e crianças. Brasília: Ministério da Saúde, 2003.
23. Daher EF, Silva GB Jr, Barros FAS et al. Clinical and laboratory features of disseminated histoplasmosis in HIV patients from Brazil. Trop Med Int Health 2007; 12: 1108-15.
24. De Franchesco Daher E, Barros FAS, da Silva Júnior GB et al. Risk factors for death in acquired immunodeficiency syndrome-associated disseminated histoplasmosis. Am J Trop Med Hyg 2006; 74: 600-3.
25. BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Boletim Epidemiológico - AIDS e DST, Brasília: Ministério da Saúde, 2010.
26. Huber F, Nacher M, Aznar C et al. AIDS-related Histoplasma capsulatum var. capsulatum infection: 25 years experience of French Guiana. AIDS 2008; 22: 1047-53.
27. Couppie P, Sobesky M, Aznar C et al. Histoplasmosis and Acquired Immunodeficiency Syndrome: a study of prognostic factors. Clin Infect Dis 2004; 38: 134-8.
28. Couppie P, Clity E, Nacher M, Aznar C, Sainte-Marie D, Carme B, Pradinaud R. Acquired immunodeficiency syndrome-related oral and/or cutaneous histoplasmosis: a descriptive and comparative study of 21 cases in French Guiana. Int J Dermatol 2002; 41: 571-5.
29. CEARÁ. Governo do Estado. Secretaria de Saúde do Estado. Informe Epidemiológico AIDS. Fortaleza, 2011.
30. Chang MR, Taira CL, Paniago AMM, Taira DL, Cunha RV, Wanke B. Study of 30 cases of histoplasmosis observed in the Mato Grosso do Sul State, Brazil. Rev Inst Med Trop S Paulo 2007; 49: 37-9.
31. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46(Suppl. 1): 3-8.
32. Girardi E, Sampaolesi A, Gentile M, Nurra G, Ippolito G. Increasing proportion of late diagnosis of HIV infection among patients with AIDS in Italy following introduction of combination antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25: 71-6.
33. Althoff KN, Gange SJ, Klein MB et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010; 50: 1512-20.
34. Girardi E, Aloisi MS, Arici C et al. Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr 2004; 36: 951-9.
35. Fernandes JR, Acurcio FA, Campos LN, Guimarães MDC. Inicio da terapia anti-retroviral em estagio avancado de imunodeficiencia entre individuos portadores de HIV/AIDS em Belo Horizonte, Minas Gerais, Brasil. Cad Saude Publica 2009; 25: 1369-80.
36. Grangeiro A, Escuder MM, Menezes PR, Alencar R, Castilho EA. Late entry into HIV care: estimated impact on AIDS mortality rates in Brazil, 2003-2006. PLoS ONE 2011; 6: e14585.
37. Guibu AI, Barros MBA, Donalísio MR, Tayra A, Alves MCGP. Survival of AIDS in the Southeast and South of Brazil: analysis of the 1998-1999 cohort. Cad Saude Publica 2011; 27(Suppl. 1): 579-92.
38. Ramos AN Jr, Matida LH, Hearst NG, Heukelbach J. AIDS morbidity and mortality in Brazilian children before and after HAART implementation: an assessment of regional trends. Pediatr Infect Dis J 2011; 30: 773-7.
39. Ramos AN Jr, Matida LH, Hearst NG, Heukelbach J. Opportunistic illnesses in Brazilian children with AIDS: results from two national cohort studies, 1983-2007. AIDS Res Ther 2011; 8: 23.
40. Fagundes VHV, Oliveira JHT, Vieira S, Spack Junior M, Pupulin ART. Infecções oportunistas em indivíduos com infecção pelo HIV e relação com uso de terapia antiretroviral. Acta Sci Health Sci 2010; 32: 141-5.
41. Nacher M, Antoine Adenis A, Adriouch L et al. Short report: what is AIDS in the Amazon and the Guianas? Establishing the burden of disseminated histoplasmosis. Am J Trop Med Hyg 2011; 84: 239-40.
42. Leimann BCQ, Pizzini CV, Muniz MM et al. Histoplasmosis in a Brazilian center: clinical forms and laboratory tests. Rev Iberoam Micol 2005; 22: 141-6.
43. Polejack L, Seidl EMF. Monitoramento e avaliação da adesão ao tratamento antiretroviral para HIV/aids: desafios e possibilidades. Cien Saude Colet 2010; 15(Suppl. 1): 1201-8.
44. Wheat LJ, Connolly-Stringfield P, Blair R, Connolly K, Garringer T, Katz BP. Histoplasmosis relapse in patients with AIDS: detection using Histoplasma capsulatum variety capsulatum antigen levels. Ann Intern Med 1991; 115: 936-41.
45. Baddley JW, Sankara IR, Rodriguez JM, Pappas PG, Many Jr DJ. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagn Microbiol Infect Dis 2008; 62: 151-6.
46. Andrade RA, Evans RT, Hamill RJ, Zerai T, Giordano TP. Clinical evidence of interaction between itraconazole and non nucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis. Annals of Pharmacother 2009; 43: 908-13.
47. Koo HL, Hamill RJ, Andrade RA. Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Clin Infect Dis 2007; 45: 77-9.
48. Huet E, Hadji C, Hulin A, Botterel F, Bretagne S, Lévy Y. Therapeutic monitoring is necessary for the association itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. AIDS 2008; 22: 1885-96.
49. Crommentuyn KML, Mulder JW, Sparidans RW, Huitema ADR, Schellens JHM, Beijnen JH. Drug-drug interaction between Itraconazole and the antiretroviral drug Lopinavir/Ritonavir in an HIV-1 - infected patient with disseminated histoplasmosis. Clin Infect Dis 2004; 38: e73-5.